Although several genetic diseases are caused by mutations in channels made by connexin family members, there has been little progress in the development and validation of therapeutic options. An in vitro study in this issue of JID suggests that an anti-malarial drug may be beneficial in keratitis-ichthyosis deafness, a severe conexin channel disease associated with potentially fatal recurrent infections.
展开▼